Supplementary Material

Bifunctional Aptamer Drug Carrier Enabling Selective and Efficient Incorporation of an Approved Anticancer Drug Irinotecan to Fibrin Gels

Hiroto Fujita, Yuka Kataoka and Masayasu Kuwahara*

Graduate School of Integrated Basic Sciences, Nihon University, 3-25-40 Sakurajosui, Setagaya-ku, Tokyo 156-8550, Japan

*Correspondence: mkuwa@chs.nihon-u.ac.jp

Table S1. Synthetic oligonucleotides used in this study.

ODN	5′-Modification	Sequence[a]
CMA-70_Temp	Phosphate	ACACGGCTAGCACGGCGAAGAAGTTACTCTGATACTATGACCACCCTAC GTGTCTGGCGTGCCTCTGGTG
CMA-70_P1	Non	CACCAGAGGCACGCCAGACA
T1	6-FAM	CACGGCGAAGAAGTTACTCTGATACTATGACCACCCTACGTGTCTGGCG TGTCACCCCAACCTGCCCTACCACGGA
TBA_P1	Non	TCCGTGGTAGGGCAGGTTGGGGTGA

[a]Sequences are aligned in the 5′ to 3′ direction.



Figure S1. Metabolism of irinotecan to SN-38.



Figure S2. Enzymatic synthesis of bApt through a primer extension reaction. Oligo nucleic acids and products were analyzed via PAGE using a 10% denaturing gel and TBE buffer (pH 8.0) at 200 V for 35 min. Details are shown in references 27 and 30.